Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors

被引：460

作者：

Liao, Jeffrey Jie-Lou

机构：

[1] TransTech Pharma, High Point, NC 27265 USA

[2] Duke Univ, Dept Chem, Durham, NC 27708 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2007年 / 50卷 / 03期

关键词：

GROWTH-FACTOR RECEPTOR; CYCLIN-DEPENDENT KINASE; STRUCTURE-GUIDED DESIGN; ABL TYROSINE KINASE; STRUCTURAL BASIS; CRYSTAL-STRUCTURE; ANTITUMOR-ACTIVITY; DRUG DISCOVERY; AURORA KINASE; MAP KINASE;

D O I：

10.1021/jm0608107

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

[No abstract available]

引用

页码：409 / 424

页数：16

共 133 条

[21] Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].

Carter, TA ;

Wodicka, LM ;

Shah, NP ;

Velasco, AM ;

Fabian, MA ;

Treiber, DK ;

Milanov, ZV ;

Atteridge, CE ;

Biggs, WH ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Mehta, SA ;

Patel, HK ;

Pao, W ;

Sawyers, CL ;

Varmus, H ;

Zarrinkar, PP ;

Lockhart, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016

[22] Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors [J].

Chang, YT ;

Gray, NS ;

Rosania, GR ;

Sutherlin, DP ;

Kwon, S ;

Norman, TC ;

Sarohia, R ;

Leost, M ;

Meijer, L ;

Schultz, PG .

CHEMISTRY & BIOLOGY, 1999, 6 (06) :361-375

[23] Recent kinase and kinase inhibitor X-ray structures: Mechanisms of inhibition and selectivity insights [J].

Cherry, M ;

Williams, DH .

CURRENT MEDICINAL CHEMISTRY, 2004, 11 (06) :663-673

[24] Molecular design and bioavailability [J].

Clark, RD ;

Wolohan, PRN .

CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (11) :1269-1288

[25] United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets [J].

Cohen, MH ;

Williams, GA ;

Sridhara, R ;

Chen, G ;

McGuinn, WD ;

Morse, D ;

Abraham, S ;

Rahman, A ;

Liang, CY ;

Lostritto, R ;

Baird, A ;

Pazdur, R .

CLINICAL CANCER RESEARCH, 2004, 10 (04) :1212-1218

[26] Structural bioinformatics-based design of selective, irreversible kinase inhibitors [J].

Cohen, MS ;

Zhang, C ;

Shokat, KM ;

Taunton, J .

SCIENCE, 2005, 308 (5726) :1318-1321

[27] Protein kinases - the major drug targets of the twenty-first century? [J].

Cohen, P .

NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315

[28] Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds [J].

Dalgarno, D ;

Stehle, T ;

Narula, S ;

Schelling, P ;

van Schravendijk, MR ;

Adams, S ;

Andrade, L ;

Keats, J ;

Ram, M ;

Jin, L ;

Grossman, T ;

MacNeil, I ;

Metcalf, C ;

Shakespeare, W ;

Wang, Y ;

Keenan, T ;

Sundaramoorthi, R ;

Bohacek, R ;

Weigele, M ;

Sawyer, T .

CHEMICAL BIOLOGY & DRUG DESIGN, 2006, 67 (01) :46-57

[29] Issues and progress with protein kinase inhibitors for cancer treatment [J].

Dancey, J ;

Sausville, EA .

NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) :296-313

[30] Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].

Davies, SP ;

Reddy, H ;

Caivano, M ;

Cohen, P .

BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105

← 1 2 3 4 5 6 7 8 9 10 →